scholarly journals Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand

2021 ◽  
Vol Volume 13 ◽  
pp. 917-926
Author(s):  
Sermsiri Sangroongruangsri ◽  
Usa Chaikledkaew ◽  
Prut Hanusaha ◽  
Tanapat Ratanapakorn ◽  
Paisan Ruamviboonsuk
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Drug Treatments ◽  
Choroidal Vasculopathy

scholarly journals A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Narisa Tantai ◽  
Usa Chaikledkaew ◽  
Tawesak Tanwandee ◽  
Pitsaphun Werayingyong ◽  
Yot Teerawattananon
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Positive Chronic Hepatitis ◽  
Drug Treatments

scholarly journals Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis

2021 ◽  
Vol 6 (1) ◽  
pp. 238146832097841
Author(s):  
Eric D. Shah ◽  
Jessica K. Salwen-Deremer ◽  
Peter R. Gibson ◽  
Jane G. Muir ◽  
Shanti Eswaran ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Prescription Drug ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Decision Analytic Model ◽  
Utility Analysis ◽  
Drug Prices ◽  
Payer Perspective ◽  
Drug Treatments ◽  
Irritable Bowel

Introduction. Irritable bowel syndrome (IBS) is the most common gastroenterology referral and one of the most common gastrointestinal complaints in primary care. We performed a cost-utility analysis of the most common treatments available in general practice for IBS with constipation (IBS-C), the most expensive IBS subtype. Methods. We developed a decision analytic model evaluating guideline-recommended and Food and Drug Administration–approved drugs, supplements, and dietary/psychological interventions. Model inputs were derived from “global symptom improvement” outcomes in systematic reviews of clinical trials. Costs were derived from national datasets. Analysis was performed with a 1-year time horizon from patient and payer perspectives. We analyzed a prototypical managed-care health plan with no cost-sharing to the patient. Results. From a payer perspective, global IBS treatments (including low FODMAP, cognitive behavioral therapy [CBT], neuromodulators), which are not specific to the IBS-C bowel subtype were less expensive than on-label prescription drug treatments. From a patient perspective, on-label prescription drug treatment with linaclotide was the least expensive treatment strategy. Drug prices and costs to manage untreated IBS-C were most important determinants of payer treatment preferences. Effects of treatment on missed work-days and need for repeated appointments to complete treatment were the most important determinants of treatment preference to patients. Discussion. Due mostly to prescription drug prices, neuromodulators, low FODMAP, and CBT appear cost-effective compared to on-label drug treatments from a payer perspective in cost-utility analysis. These findings may explain common treatment barriers in clinical practice.

Cost-utility analysis of eating disorder treatment

2011 ◽  
Author(s):  
V. Pohjolainen ◽  
P. Rasanen ◽  
R. P. Roine ◽  
H. Sintonen ◽  
K. Wahlbeck ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Eating Disorder Treatment ◽  
Disorder Treatment

Cost‐effectiveness in surgery: concepts of cost‐utility analysis explained

2021 ◽  
Author(s):  
Ravi Vissapragada ◽  
Norma Bulamu ◽  
Jonathan Karnon ◽  
Roger Yazbek ◽  
David I. Watson
Keyword(s):  
Cost Effectiveness ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis

scholarly journals QALY league table of Iran: a practical method for better resource allocation

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Reza Hashempour ◽  
Behzad Raei ◽  
Majid Safaei Lari ◽  
Nasrin Abolhasanbeigi Gallezan ◽  
Ali AkbariSari
Keyword(s):  
Heart Diseases ◽  
Evaluation Studies ◽  
Final Analysis ◽  
Practical Method ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Knowledge Network ◽  
Cochrane Library ◽  
League Table ◽  
Utility Analysis

Abstract Background The limited health care resources cannot meet all the demands of the society. Thus, decision makers have to choose feasible interventions and reject the others. We aimed to collect and summarize the results of all cost utility analysis studies that were conducted in Iran and develop a Quality Adjusted Life Year (QALY) league table. Methods A systematic mapping review was conducted to identify all cost utility analysis studies done in Iran and then map them in a table. PubMed, Embase, Cochrane library, Web of Science, as well as Iranian databases like Iran Medex, SID, Magiran, and Barakat Knowledge Network System were all searched for articles published from the inception of the databases to January 2020. Additionally, Cost per QALY or Incremental Cost Utility Ratio (ICUR) were collected from all studies. The Joanna Briggs checklist was used to assess quality appraisal. Results In total, 51 cost-utility studies were included in the final analysis, out of which 14 studies were on cancer, six studies on coronary heart diseases. Two studies, each on hemophilia, multiple sclerosis and rheumatoid arthritis. The rest were on various other diseases. Markov model was the commonest one which has been applied to in 45% of the reviewed studies. Discount rates ranged from zero to 7.2%. The cost per QALY ranged from $ 0.144 in radiography costs for patients with some orthopedic problems to $ 4,551,521 for immune tolerance induction (ITI) therapy in hemophilia patients. High heterogeneity was revealed; therefore, it would be biased to rank interventions based on reported cost per QALY or ICUR. Conclusions However, it is instructive and informative to collect all economic evaluation studies and summarize them in a table. The information on the table would in turn be used to redirect resources for efficient allocation. in general, it was revealed that preventive programs are cost effective interventions from different perspectives in Iran.

Telestroke for acute ischaemic stroke: A systematic review of economic evaluations and a de novo cost–utility analysis for a middle income country

2021 ◽  
pp. 1357633X2110324
Author(s):  
Elise Tan ◽  
Lan Gao ◽  
Huong NQ Tran ◽  
Dominique Cadilhac ◽  
Chris Bladin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Rural China ◽  
Stroke Care ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Sensitivity Analyses ◽  
Economic Evaluations ◽  
Utility Analysis

Introduction Telemedicine can alleviate the problems faced in rural settings in providing access to specialist stroke care. The evidence of the cost-effectiveness of this model of care outside high-income countries is limited. This study aimed to conduct: (a) a systematic review of economic evaluations of telestroke and (b) a cost–utility analysis of telestroke, using China as a case study. Methods We systematically searched Embase, Medline Complete and Cochrane databases. Inclusion criteria: full economic evaluations of telemedicine/telestroke networks examining the use of thrombolysis in patients with acute ischaemic stroke, published in English. A cost–utility analysis was undertaken using a Markov model incorporating a decision tree to simulate the delivery of telestroke for acute ischaemic stroke in rural China, compared to no telestroke from a societal and healthcare perspective. One-way deterministic sensitivity analyses and probabilistic sensitivity analyses were performed to test the robustness of results. Results Of 559 publications found, eight met the eligibility criteria and were included in the systematic review (two cost-effectiveness analyses and six cost–utility analyses, all performed in high-income countries). Telestroke was a cost-saving/cost-effective intervention in five out of the eight studies. In our modelled analysis for rural China, telestroke was the dominant strategy, with estimated cost savings of Chinese yuan 4,328 (US$627) and additional 0.0925 quality-adjusted life years per patient. Sensitivity analyses confirmed the base case results. Discussion Consistent with published economic evaluations of telestroke in other jurisdictions, telestroke represents a cost-effective solution to enhance stroke care in rural China.

Sign in / Sign up

Export Citation Format

Share Document